| Identification | Back Directory | [Name]
HC-5404-Fu | [CAS]
3034479-99-4 | [Synonyms]
HC-5404-Fu
3-Pyridinecarboxamide, 2-amino-5-[4-[[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]amino]-2-methylphenyl]-N-(1-methylethyl)-, (2E)-2-butenedioate (2:1) |
| Hazard Information | Back Directory | [Uses]
HC-5404-Fu is a PERK inhibitor with an antitumor activity. HC-5404-Fu inhibits endoplasmic reticulum stress response signalling. HC-5404-Fu sensitizes renal cell carcinoma cells to vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors (TKIs). HC-5404-Fu is promising for research of renal cell carcinoma, gastric cancer, metastatic breast cancer, small cell lung cancer, and other solid tumors[1][2][3]. | [References]
[1] Lines CL, et al. The integrated stress response in cancer progression: a force for plasticity and resistance. Front Oncol. 2023 Aug 3;13:1206561. DOI:10.3389/fonc.2023.1206561
[2] Al-Rawi DH, et al. Targeting chromosomal instability in patients with cancer. Nat Rev Clin Oncol. 2024 Sep;21(9):645-659. DOI:10.1038/s41571-024-00923-w
[3] Al Azzani M, et al. Phytochemical-mediated modulation of autophagy and endoplasmic reticulum stress as a cancer therapeutic approach. Phytother Res. 2024 Jul 3. DOI:10.1002/ptr.8283 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|